BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update.
To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.
About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$21.66 |
| Daily Change: | 0.12 0.56 |
| Daily Volume: | 478,247 |
| Market Cap: | US$1.000B |
April 07, 2025 January 13, 2025 December 16, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
